Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 1 Flow chart of included patients for analyses

Published byΕἰλείθυια Βαρνακιώτης Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 1 Flow chart of included patients for analyses"— Presentation transcript:

1 Fig. 1 Flow chart of included patients for analyses
Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Rheumatology (Oxford), Volume 58, Issue 5, 19 December 2018, Pages 840–848, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Fig. 1 Flow chart of included patients for analyses"

Similar presentations

Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.

Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Fig. 1 Flow chart of the literature search

Fig. 1 Flow chart of the literature search
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
(A) Mean (s.d.) ... (A) Mean (s.d.) baseline values for study variables for patients with and without tophi. (B) Baseline (s.d.) quality of life scores.

(A) Mean (s.d.) ... (A) Mean (s.d.) baseline values for study variables for patients with and without tophi. (B) Baseline (s.d.) quality of life scores.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
(A) mSchober in DESIR; (B) mSchober in SPACE; (C) LSF ...

(A) mSchober in DESIR; (B) mSchober in SPACE; (C) LSF ...
Fig. 1. Relative potency ratios of 13 active ingredients used against a fall armyworm population collected in Puerto ... Fig. 1. Relative potency ratios.

Fig. 1. Relative potency ratios of 13 active ingredients used against a fall armyworm population collected in Puerto ... Fig. 1. Relative potency ratios.
(A–B) Images of US ... (A–B) Images of US assessment of both patients who developed peripheral arthritis during vedolizumab treatment undergoing US-guided.

(A–B) Images of US ... (A–B) Images of US assessment of both patients who developed peripheral arthritis during vedolizumab treatment undergoing US-guided.
Fig. 1 Bone scintigraphy of the right tibia of the patient at disease onset (A), after 10 years of calcitonin ... Fig. 1 Bone scintigraphy of the right.

Fig. 1 Bone scintigraphy of the right tibia of the patient at disease onset (A), after 10 years of calcitonin ... Fig. 1 Bone scintigraphy of the right.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
AHA: American Heart Association; ALT: ...

AHA: American Heart Association; ALT: ...
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
Fig. 1 CT demonstrating aortic wall thickening with renal artery involvement (short arrow). There is also subtle ... Fig. 1 CT demonstrating aortic wall.

Fig. 1 CT demonstrating aortic wall thickening with renal artery involvement (short arrow). There is also subtle ... Fig. 1 CT demonstrating aortic wall.
Source: Figure created by the author based on data ...

Source: Figure created by the author based on data ...
(A) OA patients with ... (A) OA patients with crystals exhibit an increase in FA levels in SF compared with OA patients without crystals. (B) Patients.

(A) OA patients with ... (A) OA patients with crystals exhibit an increase in FA levels in SF compared with OA patients without crystals. (B) Patients.
bDMARD: biologic DMARD.

bDMARD: biologic DMARD.

Similar presentations

Ads by Google